Cargando…

Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023

Recently, the remarkable success of chimeric antigen receptor T cell (CAR-T) therapy in treating certain tumors has led to numerous studies exploring its potential application to treat non-oncology diseases. This review discusses the progress and evolution of CAR-T cell therapies for treating non-on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Ming-Yao, Li, Wanyang, Chen, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Immunotherapy - Other
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566417/ https://www.ncbi.nlm.nih.gov/pubmed/37814513 http://dx.doi.org/10.1080/21645515.2023.2251839

Ejemplares similares

Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)
por: Kline, Kathryn, et al.
Publicado: (2023)

IMMU-02. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL NEUROTOXICITY CORRELATES WITH PRETREATMENT AND ACUTE CSF NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS
por: Gust, Juliane, et al.
Publicado: (2020)

CD38 as a pan-hematologic target for chimeric antigen receptor T cells
por: Glisovic-Aplenc, Tina, et al.
Publicado: (2023)

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma
por: Brammer, Jonathan E, et al.
Publicado: (2021)

IMMU-14. SynNotch chimeric antigen receptor (CAR) T-cells as a potential treatment for diffuse intrinsic pontine glioma (DIPG)/diffuse midline glioma (DMG)
por: Ferrerosa, Lauren, et al.
Publicado: (2022)

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function
por: Leung, Isabel, et al.
Publicado: (2022)

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Chimeric antigen receptor T cell therapies for thoracic cancers—challenges and opportunities
por: Chan, Jack D., et al.
Publicado: (2020)

Progress in Guillain–Barré syndrome immunotherapy—A narrative review of new strategies in recent years
por: Yao, Jiajia, et al.
Publicado: (2023)

Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2021)

Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy
por: Song, Zhiqiang, et al.
Publicado: (2023)

Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies
por: Lopez, Ernesto, et al.
Publicado: (2023)

IMMU-18. Targeting Antigen Presenting Cells to improve virotherapy efficacy in Diffuse Midline Gliomas
por: Labiano, Sara, et al.
Publicado: (2022)

Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy
por: Berger, Susanna Carolina, et al.
Publicado: (2022)

CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience
por: Palomba, M Lia, et al.
Publicado: (2022)

IMMU-06. T-CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: DIVERSITY IN CELL SURFACE ANTIGEN AND HLA EXPRESSION NECESSITATES A MULTI-PRONGED APPROACH
por: Houke, Haley, et al.
Publicado: (2020)

SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report
por: McNerney, Kevin Owen, et al.
Publicado: (2023)

The FDA’s Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
por: Marks, Peter
Publicado: (2019)

Chimeric Antigen Receptor Regulatory T Cell in Transplantation: The Future of Cell Therapy?
por: Lamarche, Caroline, et al.
Publicado: (2022)

Chemokine-Adjuvanted Plasmid DNA Induces Homing of Antigen-Specific and Non–Antigen-Specific B and T Cells to the Intestinal and Genital Mucosae
por: Aldon, Yoann, et al.
Publicado: (2020)

IL-7 producing immunotherapy improves ex vivo T cell functions of immunosenescent patients, especially post hip fracture
por: Marton, Chrystel, et al.
Publicado: (2023)

CD8 T Cell Tolerance to a Tumor-Associated Self-Antigen Is Reversed by CD4 T Cells Engineered To Express the Same T Cell Receptor
por: Ghorashian, Sara, et al.
Publicado: (2015)

Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
por: Schwerdtfeger, Melanie, et al.
Publicado: (2021)

Chimeric Antigen Receptor (CAR) Regulatory T-Cells in Solid Organ Transplantation
por: Gille, Ilse, et al.
Publicado: (2022)

Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies
por: Cordas dos Santos, David M., et al.
Publicado: (2022)

A narrative review of chimeric antigen receptor-T (CAR-T) cell therapy for lung cancer
por: Liu, Yujia, et al.
Publicado: (2021)

Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion
por: Lamarche, Caroline, et al.
Publicado: (2023)

Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
por: Thompson, Jeffrey C, et al.
Publicado: (2020)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders – Advances and challenges
por: Goswami, Tapas Kumar, et al.
Publicado: (2022)

Chimeric non-antigen receptors in T cell-based cancer therapy
por: Guo, Jitao, et al.
Publicado: (2021)

Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation
por: Proics, Emma, et al.
Publicado: (2022)

Chimeric antigen receptor modified T-cells for cancer treatment
por: Han, Xiao, et al.
Publicado: (2018)

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
por: Han, Xiao, et al.
Publicado: (2019)

COVID-19 Vaccination and Anti-CD19 CAR T Cell-Induced B Cell Aplasia
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
por: Dai, Hanren, et al.
Publicado: (2016)

Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2022)

Epitope-based precision immunotherapy of Type 1 diabetes
por: Firdessa Fite, Rebuma, et al.
Publicado: (2023)

The complicated use of dupilumab in the treatment of atypical generalized pemphigus erythematosus: A report of two cases
por: Chen, Jie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3bpvij6td9qi10lr0mugva4k4m